Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Rheumatology Reports
Erschienen in: Current Rheumatology Reports 1/2011

01.02.2011

Use of Hydroxychloroquine to Prevent Thrombosis in Systemic Lupus Erythematosus and in Antiphospholipid Antibody–Positive Patients

Erschienen in: Current Rheumatology Reports | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Hydroxychloroquine is used extensively in the treatment of systemic lupus erythematosus, not only for its benefit for cutaneous and musculoskeletal lupus, but also for its role in preventing flares, preventing renal and central nervous system lupus, and improving survival rates. Hydroxychloroquine also has known benefits in reducing some traditional cardiovascular risk factors, such as hyperlipidemia and diabetes mellitus. This article reviews its possible role as an antithrombotic drug in the general population, in systemic lupus erythematosus, and in patients with antiphospholipid antibodies.
Literatur
1.
Madow BP: Use of anti-malarial drugs as “desludging” agents in vascular disease processes. JAMA 1960, 172:1630–1633.
2.
Cecchi E, Ferraris D: Desludging action of hydroxychloroquine in rheumatoid arthritis. Acta Rheumatol Scand 1962, 8:214–221.CrossRef
3.
Ernst E, Rose M, Lee R: Modification of trans-operative changes in blood fluidity by hydroxy-chloroquine. A possible explanation for the drugs anti-thrombotic effect. Pharmatherapeutica 1984, 4:48–52.PubMed
4.
Bird HA, Harkness J, Wright V: Some rheological properties of blood during anti-rheumatoid therapy. Pharmatherapeutica 1981, 3:36–39.PubMed
5.
Winocour PD, Kinlough-Rathbone RL, Mustard JF: The effect of the phospholipase inhibitor mepacrine on platelet aggregation, the platelet release reaction and fibrinogen binding to the platelet surface. Thromb Haemost 1981, 45:257–262.PubMed
6.
Carter AE, Eban R, Perrett RD: Prevention of post-operative deep venous thrombosis and pulmonary embolism. Br Med J 1971, 1:312–314.CrossRefPubMed
7.
Kinlough-Rathbone RL: Platelets, Drugs and Thrombosis. The Effects of Some Other Drugs in Platelet Function. Basel, Switzerland: Karger; 1975.
8.
Espinola RG, Pierangeli SS, Gharavi AE, Harris EN: Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost 2002, 87:518–522.PubMed
9.
Rand JH, Wu XX, Quinn AS, et al.: Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers. Blood 2008, 112:1687–1695.CrossRefPubMed
10.
Rand JH, Wu XX, Quinn AS, et al.: Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. Blood 2010, 115:2292–2299.CrossRefPubMed
11.
Rosenberg FJ, Phillips PG, Druzba PG: Use of a rabbit extracarporeal shunt in the assay of antithrombotic and thrombotic drugs. In Platelets and Thrombosis. Baltimore, MD: Baltimore University Park Press; 1974:233–234.
12.
Ziegler HK, Unanue ER: Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells. Proc Natl Acad Sci U S A 1982, 79:175–178.CrossRefPubMed
13.
Fox RI, Kang H-I: Mechanism of action of antimalarial drugs: inhibition of antigen processing and presentation. Lupus 1993, 2(Suppl 1):S9–S12.CrossRefPubMed
14.
Lafyatis R, York M, Marshak-Rothstein A: Antimalarial agents: closing the gate on Toll-like receptors? Arthritis Rheum 2006, 54:3068–3070.CrossRefPubMed
15.
Kyburz D, Brentano F, Gay S: Mode of action of hydroxychloroquine in RA—evidence of an inhibitory effect on Toll-like receptor signaling. Nat Clin Pract Rheumatol 2006, 2:458–459.CrossRefPubMed
16.
Raschi E, Borghi MO, Grossi C, et al.: Toll-like receptors: another player in the pathogenesis of the anti-phospholipid syndrome. Lupus 2008, 17:937–942.CrossRefPubMed
17.
Salmeron G, Lipsky PE: Immunosuppressive potential of antimalarials. Am J Med 1983, 75(Suppl):19–24.CrossRefPubMed
18.
Wallace DJ, Linker-Israeli M, Hyun S, et al.: The effect of hydroxychloroquine therapy on serum levels of immunoregulatory molecules in patients with systemic lupus erythematosus. J Rheumatol 1994, 21:375–376.PubMed
19.
van den Borne BE, Dijkmans BA, de Rooij HH, et al.: Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells. J Rheumatol 1997, 24:55–60.PubMed
20.
Weber SM, Levitz SM: Chloroquine interferes with lipopolysaccharide-induced TNF-alpha gene expression by a nonlysosomotropic mechanism. J Immunol 2000, 165:1534–1540.PubMed
21.
Bygbjerg IC, Svenson M, Theander TG, Bendtzen K: Effect of antimalarial drugs on stimulation and interleukin 2 production of human lymphocytes. Int J Immunopharmacol 1987, 9:513–519.CrossRefPubMed
22.
Sorice M, Longo A, Capozzi A, et al.: Anti-beta2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor alpha and tissue factor by signal transduction pathways involving lipid rafts. Arthritis Rheum 2007, 56:2687–2697.CrossRefPubMed
23.
Doring Y, Hurst J, Lorenz M, et al.: Human antiphospholipid antibodies induce TNFalpha in monocytes via Toll-like receptor 8. Immunobiology 2010, 215:230–241.CrossRefPubMed
24.
Berman J, Girardi G, Salmon JE: TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol 2005, 174:485–490.PubMed
25.
Goldman FD, Gilman AL, Hollenback C, et al.: Hydroxychloroquine inhibits calcium signals in T cells: a new mechanism to explain its immunomodulatory properties. Blood 2000, 95:3460–3466.PubMed
26.
Fontagne J, Roch-Arveiller M, Giroud JP, Lechat P: Effects of some antimalarial drugs on rat inflammatory polymorphonuclear leukocyte function. Biomed Pharmacother 1989, 43:43–51.CrossRefPubMed
27.
Segal-Eiras A, Segura GM, Babini JC, et al.: Effect of antimalarial treatment on circulating immune complexes in rheumatoid arthritis. J Rheumatol 1985, 12:87–89.PubMed
28.
Edwards MH, Pierangeli S, Liu X, et al.: Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation 1997, 96:4380–4384.PubMed
29.
Carter AE, Eban R: Prevention of postoperative deep venous thrombosis in legs by orally administered hydroxychloroquine sulphate. Br Med J 1974, 3:94–95.CrossRefPubMed
30.
Wu TK, Tsapogas MJ, Jordan FR: Prophylaxis of deep venous thrombosis by hydroxychloroquine sulfate and heparin. Surg Gynecol Obstet 1977, 145:714–718.PubMed
31.
Johnson R, Charnley J: Hydroxychloroquine in prophylaxis of pulmonary embolism following hip arthroplasty. Clin Orthoped 1979, 144:174–177.
32.
Chrisman DO, Snook GA, Wilson TC, Short JY: Prevention of venous thromboembolism by administration of hydroxychloroquine. J Bone Joint Surg 1976, 58A:918–920.
33.
Hansen EH, Jessing P, Lindewald H, et al.: Hydroxychloroquine sulphate in prevention of deep venous thrombosis following fracture of the hip, pelvis or thoracolumbar spine. J Bone Joint Surg 1976, 58A:1089–1093.
34.
Sanchez-Guerrero J, Fragoso-Loyo HE, Neuwelt CM, et al.: Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy. J Rheumatol 2008, 35:1567–1575.PubMed
35.
Johansson E, Forsberg K, Johnsson H: Clinical and experimental evaluation of the thromboprophylactic effect of hydroxychloroquine sulfate after total hip replacement. Haemostasis 1981, 10:89–96.PubMed
36.
Cooke ED, Dawson MHO, Ibbotson RM, et al.: Failure of orally administered hydroxychloroquine sulphate to prevent venous thromboembolism following elective hip operations. J Bone Joint Surg 1977, 59A:496–500.
37.
Loudon JR: Hydroxychloroquine and postoperative thromboembolism after total hip replacement. Am J Med 1988, 85(Suppl 4A):57–61.CrossRefPubMed
38.
Wallace D: Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus? [letter]. Arthritis Rheum 1987, 30:1435–1436.CrossRefPubMed
39.
Petri M, Hellmann D, Hochberg M, et al.: Arterial thrombotic events (TE) in SLE: the Baltimore Lupus Cohort study [abstract]. Arthritis Rheum 1994, 37(Suppl 9):S297.
40.
Ruiz-Irastorza G, Egurbide MV, Pijoan JI, et al.: Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 2006, 15:577–583.CrossRefPubMed
41.
• Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM: Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum 2009, 61:29–36. This was a case-control study showing that aspirin and HCQ are both protective (P=0.05) against thrombosis in antiphospholipid antibody–positive SLE patients. PubMed
42.
• Jung H, Bobba R, Su J, et al.: The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum 2010, 62:863–868. This recent nested case-control study confirmed that HCQ is protective against thrombosis, adjusting for disease severity, disease duration, and calendar year. CrossRefPubMed
43.
Erkan D, Yazici Y, Peterson MG, et al.: A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford) 2002, 41:924–929.CrossRef
Metadaten
Titel
Use of Hydroxychloroquine to Prevent Thrombosis in Systemic Lupus Erythematosus and in Antiphospholipid Antibody–Positive Patients
Publikationsdatum
01.02.2011
Erschienen in
Current Rheumatology Reports / Ausgabe 1/2011
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-010-0141-y

Weitere Artikel der Ausgabe 1/2011

Current Rheumatology Reports 1/2011 Zur Ausgabe

ReviewPaper

The Scleroderma Kidney: Progress in Risk Factors, Therapy, and Prevention

ReviewPaper

The Genetics of Scleroderma

ReviewPaper

Autoantibodies Directed Against Domain I of Beta2-Glycoprotein I

ReviewPaper

Update on Antiphospholipid Syndrome in Children

ReviewPaper

Imatinib and the Treatment of Fibrosis: Recent Trials and Tribulations

ReviewPaper

Biomarkers in the Management of Scleroderma: An Update

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise